Floatz logo

Herombopag

Chemotherapy-induced Thrombocytopenia

Institute of Hematology & Blood Diseases Hospital, ChinaPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

18 Active assets in the Chemotherapy-induced Thrombocytopenia cohort.

Asset / SponsorPhaseRating
Recombinant Human Thrombopoietin
Sun Yat-sen University
Phase 4BBB
sb-497115-gr
Institute of Hematology & Blood Diseases Hospital, China
Phase 4BB
FILGRASTIM
OHSU Knight Cancer Institute
Phase 2BB
Avatrombopag
Second Affiliated Hospital of Guangzhou Medical University
Phase 4BB
Hetrombopag
Sun Yat-sen University
Phase 3BB

View all 50 →

Same molecule, other indications

Herombopag is also rated in:

thrombocytopenia due to immune destructionDormant
B
Indicative ·
60 / 100
View asset →
HER2 positive breast carcinomaDormant
D
Indicative ·
28 / 100
View asset →
HerombopagDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →